Login to Your Account



Other News To Note


Thursday, May 31, 2012
• Dyax Corp., of Burlington, Mass., said Leverkusen, Germany-based Bayer Pharma AG executed a license to Dyax's antibody phage display technology for development and potential commercialization of therapeutic antibody candidates identified using the Dyax library. The deal was based on successful antibody discovery work during a research evaluation period. Financial terms were not disclosed.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription